Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4854358 | 0.89 | DRD2 (0.42) | DRD2ADRA1AMEN1KMT2A | |
| SCHEMBL4848028 | 0.81 | DRD2 (0.54) | DRD2ADRA1AKCNH2MCHR1DRD4 | |
| SCHEMBL4850462 | 0.78 | DRD2 (0.54) | DRD2ADRA1AKCNH2MCHR1MEN1 | |
| SCHEMBL4850559 | 0.77 | DRD2 (0.66) | DRD2ADRA1AKCNH2MCHR1MEN1 | |
| SCHEMBL4856874 | 0.77 | DRD2 (0.52) | DRD2ADRA1AKCNH2MCHR1SIGMAR1 | |
| SCHEMBL4854854 | 0.75 | DRD2 (0.61) | DRD2ADRA1AKCNH2MCHR1MEN1 | |
| SCHEMBL4848389 | 0.70 | DRD2 (0.43) | DRD2ADRA1AMEN1KMT2A | |
| SCHEMBL29960102 | 0.70 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL28514024 | 0.70 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL5661648 | 0.69 | DRD2 (1.00) | DRD2ADRA1AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446204-B2 | Amino substituted aryloxybenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2008-11-04 | — | — | US | disclosed |
| EP-1804796-A2 | AMINO SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006041636-A2 | AMINO SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES | H.LUNDBECK A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079524-A1 | Amino substituted aryloxybenzylpiperidine derivatives | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079524-A1 | Amino substituted aryloxybenzylpiperidine derivatives | MCHR1, MCHR2, MC4R | DRD2 198/4885ADRA1A 34/4885KCNH2 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.